Anthony James Culverwell Acquires 6,146 Shares of Quoin Pharmaceuticals (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Director Anthony James Culverwell purchased 6,146 shares of the firm’s stock in a transaction dated Monday, August 31st. The shares were acquired at an average cost of $4.88 per share, with a total value of $29,992.48. Following the completion of the purchase, the director directly owned 40,364 shares in the company, valued at approximately $196,976.32. This represents a 17.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Quoin Pharmaceuticals Stock Up 4.7%

Shares of QNRX stock traded up $0.29 during trading on Tuesday, reaching $6.51. The company’s stock had a trading volume of 274,471 shares, compared to its average volume of 1,602,162. The business has a fifty day moving average price of $4.77 and a 200-day moving average price of $5.89. The company has a market cap of $13.09 million, a price-to-earnings ratio of -0.26 and a beta of 1.50. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a one year low of $3.25 and a one year high of $41.80.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its earnings results on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.29). Research analysts anticipate that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on QNRX. ThinkEquity began coverage on Quoin Pharmaceuticals in a report on Monday, June 15th. They issued a “buy” rating for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, July 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Quoin Pharmaceuticals has an average rating of “Hold”.

Hedge Funds Weigh In On Quoin Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. SummitTX Capital L.P. raised its position in Quoin Pharmaceuticals by 54.8% during the first quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock worth $662,000 after acquiring an additional 35,505 shares in the last quarter. Ikarian Capital LLC bought a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at about $3,052,000. Millennium Management LLC bought a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at about $1,080,000. Boothbay Fund Management LLC acquired a new position in shares of Quoin Pharmaceuticals during the 4th quarter worth about $863,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Quoin Pharmaceuticals during the 4th quarter worth about $840,000. 8.63% of the stock is owned by institutional investors.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.